Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.

Recent News

December 14, 2011
Threshold Pharmaceuticals Announces Promising Phase 1 Clinical Trial Results in Patients With Advanced Leukemias

December 13, 2011
Threshold Pharmaceuticals Announces Update to TH-302 Pancreatic Data to Be Presented at the Oppenheimer Healthcare Conference

November 29, 2011
Threshold Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

View All Recent News